Placebo-controlled study of gabapentin treatment of panic disorder / Atul C. Pande en Journal of Clinical Psychopharmacology, Año 2000 - Vol. 20 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 4 (Agosto) . - pp. 467-471 Título : Placebo-controlled study of gabapentin treatment of panic disorder Tipo de documento: texto impreso Autores: Atul C. Pande, Autor ; Mark H. Pollack, Autor ; Jerri G. Crockatt, Autor Fecha de publicación: 2023 Artículo en la página: pp. 467-471 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Agorafobia, Aminas, Ansiolíticos, Ácidos ciclohexanocarboxílicos, Gabapentina, Trastorno de pánico, Características sexuales. Resumen: A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of panic disorder. One hundred three patients were randomly assigned to receive double-blind treatment with either gabapentin (dosed flexibly between 600 and 3,600 mg/day) or placebo for 8 weeks. Link: ./index.php?lvl=notice_display&id=31183 [artículo] Placebo-controlled study of gabapentin treatment of panic disorder [texto impreso] / Atul C. Pande, Autor ; Mark H. Pollack, Autor ; Jerri G. Crockatt, Autor . - 2023 . - pp. 467-471. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 4 (Agosto) . - pp. 467-471 Palabras clave: Agorafobia, Aminas, Ansiolíticos, Ácidos ciclohexanocarboxílicos, Gabapentina, Trastorno de pánico, Características sexuales. Resumen: A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of panic disorder. One hundred three patients were randomly assigned to receive double-blind treatment with either gabapentin (dosed flexibly between 600 and 3,600 mg/day) or placebo for 8 weeks. Link: ./index.php?lvl=notice_display&id=31183

A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder / Douglas E. Feltner en Journal of Clinical Psychopharmacology, Año 2003 - Vol. 23 - No. 3 (Junio)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 3 (Junio) . - pp. 240-249 Título : A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder Tipo de documento: texto impreso Autores: Douglas E. Feltner, Autor ; Jerri G. Crockatt, Autor ; Steven J. Dubovsky, Autor Fecha de publicación: 2023 Artículo en la página: pp. 240-249 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastornos de ansiedad, Pruebas Neuropsicológicas, Pregabalina, Ácido gamma-aminobutírico. Resumen: Pregabalin is a novel compound under development for the treatment of several types of anxiety disorders. To obtain an initial evaluation of the efficacy and safety of pregabalin in the treatment of generalized anxiety disorder (GAD), we conducted a double-blind, fixed-dose, parallel-group, placebo and active-controlled multicenter 4-week study that compared 271 patients randomized to receive pregabalin 50 mg tid (N = 70), pregabalin 200 mg tid (N = 66), placebo (N = 67), or lorazepam 2 mg tid (N = 68), followed by a 1-week double-blind taper. Link: ./index.php?lvl=notice_display&id=31020 [artículo] A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder [texto impreso] / Douglas E. Feltner, Autor ; Jerri G. Crockatt, Autor ; Steven J. Dubovsky, Autor . - 2023 . - pp. 240-249. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 3 (Junio) . - pp. 240-249 Palabras clave: Trastornos de ansiedad, Pruebas Neuropsicológicas, Pregabalina, Ácido gamma-aminobutírico. Resumen: Pregabalin is a novel compound under development for the treatment of several types of anxiety disorders. To obtain an initial evaluation of the efficacy and safety of pregabalin in the treatment of generalized anxiety disorder (GAD), we conducted a double-blind, fixed-dose, parallel-group, placebo and active-controlled multicenter 4-week study that compared 271 patients randomized to receive pregabalin 50 mg tid (N = 70), pregabalin 200 mg tid (N = 66), placebo (N = 67), or lorazepam 2 mg tid (N = 68), followed by a 1-week double-blind taper. Link: ./index.php?lvl=notice_display&id=31020

---

1 (1 - 2 / 2)